13F Data
13F filer · CIK 1587114

EcoR1 Capital, LLC

San Francisco, CA · filing since Q4 2014 · last filing Aug 14, 2026
Reported value
$2.1B
$-299.6M vs prior
Positions
33
New / sold out
11 / 8
Added / reduced
3 / 4
Turnover
11.8%
buys $261.0M · sells $831.6M
Top-10 weight
86.3%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewFIRST TRACKS BIOTHERAPEUTICS+3,174,519–+$63.9M
NewCG ONCOLOGY INCCALL+561,500–+$39.9M
AddedCG ONCOLOGY INC+392,300+35.6%+$27.9M
NewFULCRUM THERAPEUTICS INC+6,549,866–+$24.0M
NewLEGEND BIOTECH CORP+800,000–+$23.1M
AddedSTOKE THERAPEUTICS INC+635,000+635.0%+$20.8M
AddedATARA BIOTHERAPEUTICS INC+1,452,407+1458.3%+$16.7M
NewAURA BIOSCIENCES INC+1,666,667–+$11.8M
NewODYSSEY THERAPEUTICS INC+555,555–+$10.4M
NewPHARVARIS N V+235,000–+$8.1M
4 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outJAZZ PHARMACEUTICALS PLC-1,706,469-100.0%$-322.6M
Sold outCENTESSA PHARMACEUTICALS PLC-6,000,000-100.0%$-238.3M
Sold outCRINETICS PHARMACEUTICALS IN-4,288,120-100.0%$-155.7M
Sold outXENCOR INC-2,183,000-100.0%$-26.3M
ReducedRELAY THERAPEUTICS INC-1,206,814-63.4%$-22.6M
ReducedMBX BIOSCIENCES INC-388,500-50.0%$-21.4M
Sold outCENTESSA PHARMACEUTICALS PLCCALL-410,800-100.0%$-16.3M
ReducedERASCA INC-570,000-63.3%$-10.4M
Sold outREPLIMUNE GROUP INC-1,000,000-100.0%$-7.7M
ReducedMEREO BIOPHARMA GROUP PLC-12,368,855-92.5%$-3.9M
2 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2014: $197.6MQ1 2015: $268.4MQ2 2015: $285.0MQ3 2015: $219.7MQ4 2015: $318.4MQ1 2016: $286.2MQ2 2016: $253.6MQ3 2016: $325.9MQ4 2016: $314.1MQ1 2017: $395.6MQ2 2017: $563.2MQ3 2017: $750.3MQ4 2017: $888.1MQ1 2018: $997.0MQ2 2018: $1.1BQ3 2018: $1.1BQ4 2018: $999.4MQ1 2019: $1.1BQ2 2019: $989.6MQ3 2019: $791.9MQ4 2019: $1.1BQ1 2020: $957.2MQ2 2020: $1.4BQ3 2020: $1.4BQ4 2020: $1.9BQ1 2021: $2.3BQ2 2021: $2.7BQ3 2021: $2.9BQ4 2021: $3.1BQ1 2022: $3.2BQ2 2022: $2.9BQ3 2022: $3.4BQ4 2022: $3.3BQ1 2023: $3.1BQ2 2023: $4.1BQ3 2023: $3.0BQ4 2023: $3.9BQ1 2024: $4.0BQ2 2024: $3.3BQ3 2024: $2.9BQ4 2024: $2.6BQ1 2025: $1.7BQ2 2025: $1.7BQ3 2025: $2.1BQ4 2025: $2.2BQ1 2026: $2.4BQ2 2026: $2.1B
Q4 2014Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1ZYMEWORKS INCCOM22,970,388$600.4M29.19%
2ANAPTYSBIO INCCOM7,880,094$531.9M25.86%
3AKTIS ONCOLOGY INCCOM4,824,469$155.5M7.56%
4CG ONCOLOGY INCCOM1,494,300$106.2M5.16%
5ETON PHARMACEUTICALS INCCOM2,171,938$78.6M3.82%
6CRISPR THERAPEUTICS AGNAMEN AKT1,389,276$75.8M3.68%
7ORIC PHARMACEUTICALS INCCOM6,728,116$72.9M3.54%
8FIRST TRACKS BIOTHERAPEUTICSORD SHS ADDED3,174,519$63.9M3.11%
9LAKEFRONT BIOTHERAPEUTICS NVSPON ADR1,667,119$50.0M2.43%
10NEUROGENE INCCOM1,271,342$40.0M1.94%
23 more rows. Subscribe for $29/month to see every row, download the data and use the API.